Loading...
XCSE
BRAINP
Market cap1mUSD
Dec 04, Last price  
0.01DKK
1D
4.00%
1Q
-17.46%
IPO
-99.78%
Name

Brain+ A/S

Chart & Performance

D1W1MN
XCSE:BRAINP chart
P/E
P/S
5.01
EPS
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
-17.14%
Revenues
2m
-27.23%
2,699,9901,973,5964,342,9386,021,4575,272,0006,009,0003,992,2143,232,6172,352,491
Net income
-19m
L+97.58%
-447,814-389,776-582,787-462,187-1,513,000-1,279,000-7,079,752-9,679,595-19,124,815
CFO
-14m
L+240.52%
00016,3127,290,898-8,382,370-4,025,370-13,707,331

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Brain+ A/S develops digital therapeutics for Alzheimer's and dementia. The company develops cognitive stimulation therapy (CST), a therapy that treats the main symptoms of dementia; Computerized Cognitive Training, a cognitive training method for patients with mild cognitive impairment; and Starry Night, memory test for early detection and monitoring of Alzheimer's. In addition, it develops an interface for clinicians to track and trace the patient's treatment progress. The company was incorporated in 2012 and is based in Copenhagen, Denmark. Brain+ A/S was formerly a subsidiary of Brain+ Holding ApS.
IPO date
Oct 07, 2021
Employees
Domiciled in
DK
Incorporated in
DK

Valuation

Title
DKK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT